PTPN11Shp2 overexpression enhances liver cancer progression and predicts poor prognosis of patients》.pdf

Research Article PTPN11/Shp2 overexpression enhances liver cancer progression and predicts poor prognosis of patients 1, 1, 1, 1, 1 1 2 Tao Han , Dai-Min Xiang , Wen Sun , Na Liu , Huan-Lin Sun , Wen Wen , Wei-Feng Shen , 2 1 1 1 1 2 Ruo-Yu Wang , Cheng Chen , Xue Wang , Zhuo Cheng , Heng-Yu Li , Meng-Chao Wu , 3 4 1,5,⇑ 1,5,⇑ Wen-Ming Cong , Gen-Sheng Feng , Jin Ding , Hong-Yang Wang 1The International Cooperation Laboratory on Signal Transduction, Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, Shanghai 200433, China; 2The Department of Hepatic Surgery, Eastern Hepatobiliary Surgery Hospital, Shanghai 200438, China; 3The Department of Pathology, Eastern Hepatobiliary Surgery Hospital, Shanghai 200438, China; 4Department of Pathology, and Division of Biological Sciences, University of California San Diego, La Jolla, CA 92093, USA; 5National Center for Liver Cancer, Shanghai 200433, China Background Aims:We have previously reported that Shp2, a Shp2 enhanced the sensitivity of hepatoma cells upon sorafenib tyrosine phosphatase previously known as a pro-leukemogenic treatment, and patients with low Shp2 expression exhibited molecule, suppresses the initiation of hepatocellular carcinoma superior prognosis to sorafenib. (HCC). However, the role of Shp2 in HCC progression remains